Monthly Archives:

Overview of the SYNERGY Trial

Chicago—The phase 3 SYNERGY trial was presented by Kim N. Chi and colleagues during a poster session presented at the ASCO 2015 Annual Meeting [J Clin Oncol. 2015;33; abstract 5009]. The poster was titled Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. The original trial evaluated ... Read More »

Prostate Cancer Working Group 3 Results for CRPC

Chicago—The Prostate Cancer Working Group 3 (PCWG3) was an update to the PCWG2 that was published in 2008. The availability of new treatment options for men with castration-resistant prostate cancer (CRPC) has created a need for updated clinical trial guidelines for treatment pathways. PCWG3 was convened over a 3-year period with eight live meetings to create the updated guideline, with ... Read More »

Effects of Long-Term Apparent Diffusion Coefficient Helps Determine Patients Suitable for Active Surveillance

Chicago—For the treatment of prostate cancer, active surveillance (AS) requires the right selection of patients, and most studies have selected patients best suited for AS based on biopsy and prostate-specific antigen (PSA) criteria, though these measures show a significant number of patients requiring treatment for disease progression. Lower tumor apparent diffusion coefficient (ADC) values, which are derived from diffusion-weighted magnetic ... Read More »

Effects of Long-Term Androgen Therapy for Prostate Cancer

Chicago—Androgen deprivation therapy (ADT) is associated with the potential for lower side effects and better quality of life when used as a treatment for prostate cancer. However, a long-term study of side effects has not been conducted. Dawn L. Hershman and colleagues examined long-term side effects of ADT during a poster session presented at the ASCO 2015 Annual Meeting [J ... Read More »

SLCO Genes to Help Determine Response to Treatment in Prostate Cancer

Chicago—Solute carrier organic anion (SLCO) transport genes influence cellular uptake of steroids and has been associated with prostate cancer treatment outcomes. A study was discussed during a poster presentation at the ASCO 2015 Annual Meeting by Elahe A. Mostaghel and colleagues that hypothesized that, due to its steroidal structure, abiraterone (ABI) may undergo SLCO-mediated transport and may be influenced intracellularly ... Read More »

Abiraterone plus Leuprolide Acetate for the Treatment of Prostate Cancer

Chicago—A recent study examined the clinical and biological heterogeneity in patients with localized high-risk prostate cancer (LHRPC) to determine the response and resistance to abiraterone acetate (AA) plus prednisone plus leuprolide acetate compared with leuprolide acetate alone. The results of the study were presented by Eleni Efstathiou and colleagues during a session at the ASCO 2015 Annual Meeting [J Clin ... Read More »

Model Predicts 12-Week Efficacy of AA plus Prednisone

Chicago—At present, there are no known markers for predicting the efficacy of treatment with abiraterone acetate (AA) in combination with prednisone (P; AA + P) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC). Manish Kohli, MD, and colleagues recently explored a model for predicting the 12-week efficacy outcome following initiation of AA+P in a prospective clinical trial (NCT# 0195364). ... Read More »

AA plus Prednisone Safe and Effective in Patients with Nonmetastatic Prostate Cancer

Chicago—Median time to prostate specific antigen (PSA) progression in high-risk patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with 1000 mg abiraterone acetate (AA) plus 5 mg prednisone (P) daily was 28.7 months. That was among the updated results on secondary end points and safety from the IMAAGEN trial. Charles J. Ryan, MD, and colleagues reported the updated results during ... Read More »

Decline in CTC Early in Treatment and Improved Overall Survival

Chicago—In a recent analysis, there was an independent association with baseline circulating cell counts (CTC) and a 30% decline in CTC following treatment and overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) and chemotherapy. David Lorente, MD, and colleagues conducted an investigation into the value of 30% declines in CTC from baseline to ... Read More »